• Tohru Inoue
  • William D. Pennie
Conference proceedings

Table of contents

  1. Front Matter
    Pages II-XXIII
  2. Introductory Keynotes

    1. Front Matter
      Pages 1-1
    2. Ken-ichi Arai
      Pages 12-19
    3. George Orphanides, Jonathan G. Moggs, Tracy C. Murphy, John W. Edmunds, William D. Pennie
      Pages 20-28
  3. Strategy for Toxicogenomics

    1. Front Matter
      Pages 29-29
    2. Russell S. Thomas, Kevin R. Hayes, Gina M. Zastrow, Karen Tran, Sharron G. Penn, David R. Rank et al.
      Pages 31-38
    3. Andrew G. Smith, Susan Robinson, Bruce Clothier, Reginald Davies, David J. Judah, Joan Riley et al.
      Pages 39-45
  4. Technical Development (Genomics and Proteomics)

  5. Experimental Applications (1) Oncology Research

    1. Front Matter
      Pages 75-75
    2. Timothy W. Gant, Nicola J. Turton, Joan Riley, David J. Judah, Reginald Davies, Doron Lipson et al.
      Pages 82-87
    3. Makoto Shibutani, Chikako Uneyama, Naoya Masutomi, Hironori Takagi, Masao Hirose
      Pages 100-106
  6. Experimental Applications (2) Xenobiotic Metabolism

    1. Front Matter
      Pages 107-107
    2. Toshihisa Ishikawa, Megumi Yoshikawa
      Pages 109-114
    3. Michelle M. Tabb, Changcheng Zhou, Bruce Blumberg
      Pages 115-125
  7. Experimental Applications (3) Endocrine Disruptor Research

    1. Front Matter
      Pages 127-127
    2. Koji Arizono, Kazuhiro Ura, Nobuaki Tominaga, Toshinori Kai, Yuji Kohara, Taisen Iguchi
      Pages 129-134
    3. Kwong-Kwok Wong, Jun Kanno, Rita Cheng, Lyle Sasser, James Morris, Larry Anderson et al.
      Pages 141-148
    4. Hajime Watanabe, Atsuko Suzuki, Takeshi Mizutani, Hiroshi Handa, Taisen Iguchi
      Pages 149-155
    5. Masatoshi Komiyama, Tetsuya Adachi, Chisato Mori
      Pages 156-162
  8. Future Prospects and Risk Assessment

    1. Front Matter
      Pages 169-169
    2. Denise E. Robinson, Syril D. Pettit, D. Gwyn Morgan
      Pages 194-203
    3. Mike Furness, Cecelia Pearson, George Natsoulis, Alan Engelberg, Keith Bostian, Kurt Jarnagin
      Pages 204-212
  9. Back Matter
    Pages 219-228

About these proceedings


The meteoric rate at which the human genome is being sequenced has presented to the research community a vast array of newly discovered genes, which in tum has catalyzed an even more dramatic effort to decipher this voluminous data set into understanding how genes function both individually and in complex pathways that regulate the biochemistry of life. A compendium of gene expression data, enhanced by complete proteomic analysis, will enable investigators to probe into the complexities of the mechanisms of normal genetic and metabolic pathways and, subsequently, how disease occurs when they malfunction. The new science of toxicogenomics combines genomic, proteomic, and informatics technologies, and biological research can now foresee a time when there will be a full comprehension of the complex dynamic mechanisms of genetics, biochemistry, and physiology. The inherent power of toxicogenomics derives from an amalgamation of multiple scientific disciplines that were originally drawn together to facilitate sequencing the three billion bases that comprise the human genome. Traditionally, the science of toxicology has been founded upon empirical codification of dose-related effects. It has evolved to studies that are directed towards understanding the mechanisms by which individual agents cause their effects in humans. Due to technical limitations, this process has been relatively slow, since it has accomplished one chemical or one effect at a time.


DNA chip Single Nucleotide Polymorphism microarray reverse toxicology toxicogenomics

Editors and affiliations

  • Tohru Inoue
    • 1
  • William D. Pennie
    • 2
  1. 1.Center for Biological Safety and ResearchNational Institute of Health SciencesSetagaya-ku, TokyoJapan
  2. 2.Molecular and Investigative ToxicologyDrug Safety Evaluation, Pfizer PGRDGrotonUSA

Bibliographic information